Literature DB >> 32600411

Association between obesity and clinical prognosis in patients infected with SARS-CoV-2.

Shao-Hang Cai1, Wei Liao2,3, Shu-Wei Chen3,4, Li-Li Liu3,5, Si-Yao Liu6, Zhi-Dan Zheng7.   

Abstract

BACKGROUND: It is well established that obesity is a disease of sustained low-grade inflammation. However, it is currently unknown if obesity plays a role in the clinical manifestations and prognosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients. In this study, we aimed to investigate whether obesity played a role in clinical manifestations and prognosis in patients infected with SARS-CoV-2.
METHODS: This is a retrospective multicenter clinical study. A total of 96 patients hospitalized with SARS-CoV-2 infection were enrolled from Dongguan People's Hospital, Nanfang hospital and the First Affiliated Hospital of Xiamen University between 23 January and 14 February 2020. Demographic and clinical data were extracted from medical records. Acute respiratory distress syndrome (ARDS) was defined as oxygenation index (PaO2/FiO2) ≤ 300 mmHg. We grouped patients through the body mass index (BMI). Associations were examined using the t test, χ2 test and multivariate logistic forward regression test.
RESULTS: Patients with BMI <  24 were significantly younger (P = 0.025) with lower creatine kinase (P = 0.013), lower diastolic pressure blood (P = 0.035), lower serum creatinine (P = 0.012), lower lactate dehydrogenase (P = 0.001) and higher platelet count (P = 0.002). The BMI level was 20.78 ± 3.15 in patients without pneumonia compared with the patients with pneumonia (23.81 ± 3.49, P = 0.001). For patients without ARDS, an average BMI level of 22.65 ± 3.53 was observed, significantly lower than patients with ARDS (24.57 ± 3.59, P = 0.022). The mean BMI was 22.35 ± 3.56 in patients experienced with relieving the clinical symptoms or stable condition by radiographic tests, lower than patients with disease exacerbation with 24.89 ± 3.17 (P = 0.001). In addition, lymphocyte count (r = - 0.23, P = 0.027) and platelet count (r = - 0.44, P < 0.001) were negatively correlated with BMI. While hemoglobin (r = 0.267, P = 0.008), creatine kinase (r = 0.331, P = 0.001), serum creatinine (r = 0.424, P < 0.001) and lactate dehydrogenase (r = 0.343, P = 0.001) were significantly positive correlated with BMI. Multivariate analysis showed that older age (OR = 1.046, P = 0.009) and BMI ≥ 24 (OR = 1.258, P = 0.005) were independent risk factors associated ICU admission while BMI ≥ 24 (OR = 4.219, P = 0.007) was independent risk factor associated with radiographic disease exacerbation.
CONCLUSIONS: Our study found BMI was significantly associated with clinical manifestations and prognosis of patients with SARS-CoV-2 infection. For patients with increased risk, clinicians should intervene promptly to avoid disease progression.

Entities:  

Keywords:  Acute respiratory distress syndrome; Body mass index; Obesity; Pneumonia; Prognosis; SARS-CoV-2

Mesh:

Year:  2020        PMID: 32600411      PMCID: PMC7322704          DOI: 10.1186/s40249-020-00703-5

Source DB:  PubMed          Journal:  Infect Dis Poverty        ISSN: 2049-9957            Impact factor:   4.520


Background

A series of unexplained viral pneumonia cases occurred worldwide recently [1]. Subsequent studies have shown that this series of pneumonia was associated with a new coronavirus infection (SARS-CoV-2) [1, 2]. This virus epidemic is posing a huge threat to global public health [3-5]. This sudden infectious disease is mainly manifested as fever, fatigue, and cough [6, 7]. Upper respiratory symptoms are relatively rare, which may be due to the fact that the virus infects cells through angiotensin converting enzyme 2, which is mainly expressed in cells of the lower respiratory tract [8, 9]. About one-half of the patients developed dyspnoea after 1 week [6]. In severe and critical cases, it progressed rapidly (average 9 days) to acute respiratory distress syndrome (ARDS) with only mild symptoms in early stage [6, 10]. This brings difficulties in managing the infectious diseases. In order to control the epidemic better and reduce the spread of the disease, early detection, quarantine and timely treatment are the keys to management. However, it is still no very clear which cohort of the population is at high risk. Obesity is now a global health issue [11, 12]. It is well established that obesity is a disease of sustained low-grade inflammation [13, 14]. Such inflammation has been suggested to be associated with obesity related disease. A series of inflammatory markers have been proved related with both obesity and obesity associated disease. Previous research has confirmed a positive association between obesity and C-reactive protein level [15]. Similar associations have also been reported for erythrocyte sedimentation rate [16] and some other inflammatory cytokines [17, 18]. Those findings further support the potential association between obesity and inflammation. The interactions between obesity and infectious diseases have recently received increasing recognition. Previously published data have indicated an association between obesity and poor outcome in pandemic H1N1 influenza infection [19]. Obesity is an established risk factor for surgical-site infections, nosocomial infections, periodontitis and skin infections [20]. However, it is currently unknown if obesity plays a role in the clinical manifestations and prognosis of SARS-CoV-2 infected patients. In this study, the clinical manifestations and clinical outcomes of SARS-CoV-2 infected patients were evaluated. The purpose of this study was to determine the role of obesity in the prognoses of patients infected with SARS-CoV-2.

Subjects and methods

Subjects

This is a retrospective multicentre clinical study. This study was approved by the institutional ethics board of Nanfang Hospital, Southern Medical University. All consecutive patients with confirmed SARS-CoV-2 infection in Dongguan People’s Hospital, Nanfang hospital affiliated Southern Medical University and the First Affiliated Hospital of Xiamen University between 23 January and 14 February 2020 were enrolled. Oral consent was obtained from patients. All patients were diagnosed with SARS-CoV-2 by pharyngeal swab samples. The SARS-CoV-2 infection diagnostic standard is detection of two target genes of SARS-CoV-2 in pharyngeal swab samples using polymerase chain reaction (PCR) [10].

Data collection

We collected patient medical records and recorded patient demographic and clinical data. All data were reviewed by a team of experienced physicians. ARDS was defined as acute onset, oxygenation index (PaO2/FiO2) ≤ 300 mmHg, and a chest radiograph that showed patchy shadows [21]. We categorized patients based on body mass index (BMI, kg/m2). All BMIs were calculated based on the height and weight measured on admission.

Statistical analysis

Continuous variables were expressed as average values and compared with student t-test. The categorical variables were expressed as a number (percentage) and compared by chi-square test. A univariate and multivariate regression analysis was used, with the results presented as an odds ratio (OR) with a 95% confidence interval (CI). All analyses were performed using SPSS software package (version 13.0, SPSS Inc. Chicago, USA), alpha level was 0.05.

Results

Characteristics of patients infected SARS-CoV-2 grouped by BMI

A total of 96 patients infected with SARS-CoV-2 were enrolled. Among these, 59 had a BMI <  24 and 37 of them had a BMI ≥ 24. Demographic and clinical characteristics were compared and shown in Table 1. Patients with BMI < 24 were significantly younger than others (P = 0.025), while the creatine kinase (CK) (P = 0.013), diastolic pressure blood (DBP), serum creatinine (P = 0.012) and lactate dehydrogenase (LDH) (P = 0.001) level were significantly lower. Platelet counts (P = 0.002) were significantly higher in patients with BMI < 24.
Table 1

The demographics and clinical characteristics between patients with COVID-19

CharacteristicGroupP value
BMI < 24BMI ≥ 24
Sample size, n5937
Sex (male), n (%)31 (52.5)23 (62.2)0.355
Age (years)35.41 ± 18.4544.00 ± 17.230.025
Systolic blood pressure124.84 ± 16.11126.29 ± 15.510.666
Diastolic blood pressure81.13 ± 9.6185.57 ± 10.080.035
Creatine kinase84.04 ± 112.12169.37 ± 212.250.013
Serum lactic acid1.64 ± 0.701.39 ± 0.650.123
Neutrophil count3.33 ± 1.503.31 ± 1.410.927
Lymphocyte count1.46 ± 1.041.19 ± 0.610.169
Hemoglobin139.22 ± 15.07142.51 ± 19.950.361
Platelet count222.23 ± 66.42180.89 ± 51.920.002
Serum creatinine60.58 ± 19.0970.19 ± 15.180.012
ALT20.38 ± 16.6526.22 ± 18.510.118
AST21.70 ± 8.5926.05 ± 13.880.065
Lactate dehydrogenase177.82 ± 54.39221.94 ± 73.210.001
Smoking tobacco, n (%)5 (8.5)3 (8.1)0.950

ALT Alanine aminotransferase; AST Aspartate aminotransferase

The demographics and clinical characteristics between patients with COVID-19 ALT Alanine aminotransferase; AST Aspartate aminotransferase We also analyzed the difference of clinical characteristics between patients with age < 18 and ≥ 18 years old. We found that patients younger than 18 years (n = 15) had lower systolic blood pressure (SBP) and DBP than adults (n = 81) (SBP: 114.67 ± 12.98 vs 127.01 ± 15.62 mmHg, P = 0.011; DBP: 75.25 ± 8.52 vs 84.02 ± 9.73 mmHg, P = 0.004). The average level of lymphocyte count in patients younger than 18 years was 2.29 ± 1.63, which was significantly higher than that of ≥ 18-year age group (1.18 ± 0.56, P < 0.001). However, no significantly different with CK level and lactate level was found between the two groups.

Association between BMI and clinical outcomes of SARS-CoV-2 infected patients

To further evaluate the association between BMI and the clinical outcomes of SARS-CoV-2 infected patients, we measured the proportion of patients with different outcomes (see Table 2). Among 96 patients infected with SARS-CoV-2, 21 of them were without pneumonia based on the finding of computerized tomography (CT) scan, while 75 patients were diagnosed with pneumonia. The proportions of patients with negative CT results were 85.7, 14.3 and 0% for patients with BMI <  24, 24–27.9 and ≥ 28, respectively; however, in pneumonia group, the proportions were 54.7, 32.0 and 13.3% in respective BMI groups (P = 0.027). Mean BMI value was 20.78 ± 3.15 in patients without pneumonia, compared with 23.81 ± 3.49 with pneumonia (P = 0.001).
Table 2

Proportion of viral pneumonia by groups

VariablePatients with COVID-19P value
Without pneumonian = 21, n (%)With pneumonian = 75, n (%)
BMI stage0.027
  < 2418 (85.7)41 (54.7)
 24–27.93 (14.3)24 (32.0)
  ≥ 280 (0)10 (13.3)
BMI level20.78 ± 3.1523.81 ± 3.490.001
Proportion of viral pneumonia by groups Among the whole cohort, 25 patients were diagnosed with ARDS. The proportions of patients with ARDS with a BMI < 24, 24–27.9, and ≥ 28 were 52.0, 24.0, and 24.0%, respectively, which were significantly different from the proportions of 64.8, 29.6 and 5.6% in patients without ARDS (P = 0.035). Average BMI was 22.65 ± 3.53 in patients without ARDS, which was significantly lower than that of patients with ARDS (24.57 ± 3.59, P = 0.022, Table 3).
Table 3

Proportion of ARDS by groups

VariablePatients with COVID-19P value
Without ARDSn = 71, n (%)With ARDSn = 25, n (%)
BMI stage0.035
< 2446 (64.8)13 (52.0)
24–27.921 (29.6)6 (24.0)
≥ 284 (5.6)6 (24.0)
BMI level22.65 ± 3.5324.57 ± 3.590.022
Proportion of ARDS by groups Patients enrolled were received at least one repeat CT scan within 1 month. After treatment, 66 patients showed improved or stable disease, while 30 showed exacerbated disease. The mean BMI was 22.35 ± 3.56 in patients with disease stable or relief, which was lower than the mean BMI of 24.89 ± 3.17, present in patients with disease exacerbation (P = 0.001), as shown in Table 4.
Table 4

Proportion of clinical outcome by groups

VariablesCOVID-19 patients with diseaseP value
Stable-relieven = 66, n (%)Exacerbationn = 30, n (%)
BMI stage0.001
  < 2449 (74.2)10 (33.3)
 24–27.913 (19.7)14 (46.7)
  ≥ 284 (6.1)6 (20.0)
BMI level22.35 ± 3.5624.89 ± 3.170.001
Proportion of clinical outcome by groups

Correlation between BMI and clinical variables

Interestingly, we found several unexpected clinical variables that were significantly correlated with BMI in all enrolled SARS-CoV-2 infected patients (Fig. 1). Lymphocyte count (r = − 0.23, P = 0.027) and platelet count (r = − 0.44, P < 0.001) were negatively correlated with BMI, while haemoglobin (r = 0.267, P = 0.008), CK (r = 0.331, P = 0.001), serum creatinine (r = 0.424, P < 0.001), and LDH (r = 0.343, P = 0.001) were significantly positive correlated with BMI.
Fig. 1

Correlation between BMI and clinical variables in SARS-CoV-2 infected patients. a Correlation between lymphocyte and BMI (r = − 0.23, P = 0.027). b Correlation between haemoglobin and BMI (r = 0.267, P = 0.008). c Correlation between platelet count and BMI (r = − 0.44, P < 0.001). d Correlation between CK level and BMI (r = 0.331, P = 0.001). e Correlation between serum creatinine and BMI (r = 0.424, P < 0.001). f Correlation between LDH and BMI (r = 0.343, P = 0.001). BMI, Body mass index. CK, creatine kinase. LDH, lactate dehydrogenase

Correlation between BMI and clinical variables in SARS-CoV-2 infected patients. a Correlation between lymphocyte and BMI (r = − 0.23, P = 0.027). b Correlation between haemoglobin and BMI (r = 0.267, P = 0.008). c Correlation between platelet count and BMI (r = − 0.44, P < 0.001). d Correlation between CK level and BMI (r = 0.331, P = 0.001). e Correlation between serum creatinine and BMI (r = 0.424, P < 0.001). f Correlation between LDH and BMI (r = 0.343, P = 0.001). BMI, Body mass index. CK, creatine kinase. LDH, lactate dehydrogenase

Univariate and multivariate analysis of factors associated with ICU admission

Logistic regression was performed to identify factors that were significantly associated with ICU admission in SARS-CoV-2-infected patients. The results of this multivariate analysis indicated that older age (OR = 1.046, P = 0.009) and BMI ≥ 24 (OR = 1.258, P = 0.005) were independent risk factors associated with ICU admission among patients with SARS-CoV-2 infection (Table 5).
Table 5

Factors associated with ICU admission

VariablesUnivariate analysisMultivariate analysis
OR95% CIP valueOR95% CIP value
Sex (male vs female)1.3610.595–3.1120.465
Age1.0431.017–1.0700.0011.0461.011–1.0810.009
Systolic blood pressure1.0260.998–1.0550.065
Diastolic blood pressure1.0230.980–1.0680.295
Creatine kinase1.0020.999–1.0040.256
Serum lactic acid0.9560.496–1.8430.894
Neutrophil count0.9190.689–1.2270.569
Lymphocyte count0.5320.274–1.0320.062
Hemoglobin1.0160.992–1.0400.198
Platelet count0.9920.985–1.0000.041
Serum creatinine1.0210.998–1.0450.073
ALT1.0190.995–1.0440.117
AST1.0421.002–1.0840.042
Lactate dehydrogenase1.0091.002–1.0160.016
Smoking tobacco (yes vs no)1.0410.234–4.6300.958
BMI level (< 24 vs ≥ 24)5.1902.110–12.763< 0.0011.2581.071–1.4780.005

OR Odds ratio; CI Confidence interval; ALT Alanine aminotransferase; AST Aspartate aminotransferase

Factors associated with ICU admission OR Odds ratio; CI Confidence interval; ALT Alanine aminotransferase; AST Aspartate aminotransferase

Univariate and multivariate analysis of factors associated with radiographic disease exacerbation

We also conducted logistic regression to identify factors that were associated with radiographic disease exacerbation in SARS-CoV-2 infected patients. Multivariate analyses showed that BMI ≥ 24 (OR = 4.219, P = 0.007) was independent risk factors associated with SARS-CoV-2 infected patients who experienced radiographic disease exacerbation (Table 6).
Table 6

Factors associated with radiographic exacerbation

VariablesUnivariate analysisMultivariate analysis
OR95% CIP valueOR95% CIP value
Sex (male vs female)1.0250.429–2.4480.956
Age1.0230.998–1.0480.069
Systolic blood pressure1.0090.982–1.0380.513
Diastolic blood pressure1.0010.958–1.0450.978
Creatine kinase1.0021.000–1.0050.097
Serum lactic acid1.0410.523–2.0740.909
Neutrophil count0.9790.725–1.3220.889
Lymphocyte count0.6840.350–1.3380.267
Hemoglobin1.0060.981–1.0320.630
Platelet count0.9970.990–1.0040.398
Serum creatinine1.0080.984–1.0330.503
ALT1.0170.992–1.0420.190
AST1.0250.986–1.0650.208
Lactate dehydrogenase1.0010.994–1.0080.756
Smoking tobacco (yes vs no)1.3560.302–6.0830.691
BMI level (< 24 vs ≥ 24)5.7652.255–14.734< 0.0014.2191.490–11.9440.007

OR Odds ratio; CI Confidence interval; ALT Alanine aminotransferase; AST Aspartate aminotransferase

Factors associated with radiographic exacerbation OR Odds ratio; CI Confidence interval; ALT Alanine aminotransferase; AST Aspartate aminotransferase

Discussion

In this study, we found that obesity played an important role in development of COVID-19. SARS-CoV-2 infected patients with a higher BMI were more likely to develop ARDS and to experience exacerbated disease. Moreover, we found that patients with higher BMIs had lower lymphocyte counts, lower platelet counts, and higher levels of haemoglobin, CK, creatinine, and LDH. Our results may help to stratify patients with SARS-CoV-2 infection: patients with high BMIs should receive prompt intervention to avoid disease progression. Most patients with SARS-CoV-2 infection will develop pneumonia [22]. However, a small number of patients have negative imaging findings for unclear reasons. As we know, the largest study to-date indicated that 3498 of the 3665 (95.5%) confirmed cases were diagnosed with pneumonia [23]. According to the 2019 New Coronavirus Pneumonia Diagnosis and Treatment Plan recommended by the National Health Committee of China, these patients without pneumonia showed only low fever and mild fatigue, and usually recovered after 1 week. Our research confirmed that, although SARS-CoV-2 infection was confirmed, some patients had negative CT results. In addition, our study found that this situation was more likely to occur in young patients with lower BMIs. Although the prognosis of these patients seems to be better than older patients with high BMIs, repeated CT examinations are still needed, particularly if the clinical symptoms worsen. Obesity is a common worldwide epidemic. Obesity is usually accompanied by a low-grade chronic inflammatory state, which is characterized by an increase in systemic inflammation markers [13, 16]. This mild chronic inflammation and non-specific activation of the immune system are thought to induce obesity-related diseases [13]. The reasons why obesity causes inflammation have not yet been well described, but studies have revealed that adipocytes secrete a variety of cytokines that help initiate an inflammatory response [24, 25]. In long-term chronic inflammation, a series of changes occur in the body, including in blood glucose, lipid, and hormone levels [24]. These changes are accompanied by insulin and catecholamine resistance, abnormal tissue remodelling and fibrosis [24]. Some patients with SARS-CoV-2 infections rapidly developed into critically ill patients, in which case the disease usually manifests as ARDS [6, 26]. Current research showed that the mortality rate of SARS-CoV-2 infected patients was 4–15% [6, 26]. It is therefore important to identify this population early. However, the subpopulations who became severely ill may have had moderate to low fever during the early course of the disease, and these patients are still difficult to screen. Whether obesity plays a role here is unknown, and further researches are still needed. Our results suggest high BMI is closely related to patient disease progression. At the same time, our study showed that BMI was negatively correlated with lymphocytes and platelets, but positively correlated with CK, LDH, and creatinine. Patients with SARS-CoV-2-infections often experience lymphocytopenia [4, 7]. It is unknown whether SARS-CoV-2 infection will induce immune deficiency, and whether obesity and adipocytes play a role here. However, according to the results of our study, patients who with a high BMI, even if their symptoms are not obvious, should be given sufficient attention to avoid rapid deterioration. The current study has several limitations. Firstly, this was a retrospective survey, with a relatively limited sample size. In addition, the role of obesity in the pathophysiology of SARS-CoV-2 infection requires further research to confirm. It is also an important topic to identify patients with SARS-CoV-2-associated pneumonia developing ARDS during the course of disease. This issue merits additional research.

Conclusions

Our study found that BMI was significantly related with clinical manifestations and clinical outcomes of patients with SARS-CoV-2 infections. Patients with higher BMIs were more likely to develop ARDS and to experience disease progression. Older age and high BMI are independent risk factors associated with ICU admission in SARS-CoV-2 infected patients, while patients with higher BMIa are more likely to experience disease exacerbation. For patients with risk factors, clinicians should intervene promptly to avoid disease progression.
  25 in total

Review 1.  Obesity, inflammation, and the gut microbiota.

Authors:  Amanda J Cox; Nicholas P West; Allan W Cripps
Journal:  Lancet Diabetes Endocrinol       Date:  2014-07-22       Impact factor: 32.069

Review 2.  Guideline Recommendations for Obesity Management.

Authors:  Donna H Ryan; Scott Kahan
Journal:  Med Clin North Am       Date:  2018-01       Impact factor: 5.456

3.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

Review 4.  Obesity and C-reactive protein in various populations: a systematic review and meta-analysis.

Authors:  J Choi; L Joseph; L Pilote
Journal:  Obes Rev       Date:  2012-11-22       Impact factor: 9.213

5.  Acute respiratory distress syndrome: the Berlin Definition.

Authors:  V Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Niall D Ferguson; Ellen Caldwell; Eddy Fan; Luigi Camporota; Arthur S Slutsky
Journal:  JAMA       Date:  2012-06-20       Impact factor: 56.272

6.  Risk factors associated with liver steatosis and fibrosis in chronic hepatitis B patient with component of metabolic syndrome.

Authors:  Shaohang Cai; Zejin Ou; Duan Liu; Lili Liu; Ying Liu; Xiaolu Wu; Tao Yu; Jie Peng
Journal:  United European Gastroenterol J       Date:  2018-01-16       Impact factor: 4.623

7.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

8.  Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series.

Authors:  Xiao-Wei Xu; Xiao-Xin Wu; Xian-Gao Jiang; Kai-Jin Xu; Ling-Jun Ying; Chun-Lian Ma; Shi-Bo Li; Hua-Ying Wang; Sheng Zhang; Hai-Nv Gao; Ji-Fang Sheng; Hong-Liu Cai; Yun-Qing Qiu; Lan-Juan Li
Journal:  BMJ       Date:  2020-02-19

9.  First Case of 2019 Novel Coronavirus in the United States.

Authors:  Michelle L Holshue; Chas DeBolt; Scott Lindquist; Kathy H Lofy; John Wiesman; Hollianne Bruce; Christopher Spitters; Keith Ericson; Sara Wilkerson; Ahmet Tural; George Diaz; Amanda Cohn; LeAnne Fox; Anita Patel; Susan I Gerber; Lindsay Kim; Suxiang Tong; Xiaoyan Lu; Steve Lindstrom; Mark A Pallansch; William C Weldon; Holly M Biggs; Timothy M Uyeki; Satish K Pillai
Journal:  N Engl J Med       Date:  2020-01-31       Impact factor: 91.245

10.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

View more
  18 in total

Review 1.  Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Abraham Degarege; Zaeema Naveed; Josiane Kabayundo; David Brett-Major
Journal:  Pathogens       Date:  2022-05-10

Review 2.  Obesity Impact on SARS-CoV-2 Infection: Pros and Cons "Obesity Paradox"-A Systematic Review.

Authors:  Damiana-Maria Vulturar; Carmen-Bianca Crivii; Olga Hilda Orăsan; Emanuel Palade; Anca-Dana Buzoianu; Iulia Georgiana Zehan; Doina Adina Todea
Journal:  J Clin Med       Date:  2022-07-02       Impact factor: 4.964

Review 3.  Immune Response to SARS-CoV-2 Infection in Obesity and T2D: Literature Review.

Authors:  Jorge Pérez-Galarza; César Prócel; Cristina Cañadas; Diana Aguirre; Ronny Pibaque; Ricardo Bedón; Fernando Sempértegui; Hemmo Drexhage; Lucy Baldeón
Journal:  Vaccines (Basel)       Date:  2021-01-29

4.  The Magnitude of Hematological Abnormalities Among COVID-19 Patients in Addis Ababa, Ethiopia.

Authors:  Shambel Araya; Moges Wordofa; Mintesnot Aragaw Mamo; Yakob Gebregziabher Tsegay; Abebe Hordofa; Abebe Edao Negesso; Tewodros Fasil; Betelhem Berhanu; Hermela Begashaw; Asegdew Atlaw; Tirhas Niguse; Mahlet Cheru; Zemenu Tamir
Journal:  J Multidiscip Healthc       Date:  2021-03-02

Review 5.  Obesity and COVID-19: what makes obese host so vulnerable?

Authors:  Sameer Mohammad; Rafia Aziz; Saeed Al Mahri; Shuja Shafi Malik; Esraa Haji; Altaf Husain Khan; Tanvir Saleem Khatlani; Abderrezak Bouchama
Journal:  Immun Ageing       Date:  2021-01-04       Impact factor: 6.400

Review 6.  Excess Body Mass-A Factor Leading to the Deterioration of COVID-19 and Its Complications-A Narrative Review.

Authors:  Weronika Gryczyńska; Nikita Litvinov; Bezawit Bitew; Zuzanna Bartosz; Weronika Kośmider; Paweł Bogdański; Damian Skrypnik
Journal:  Viruses       Date:  2021-12-03       Impact factor: 5.818

7.  COVID-19 autopsy cases: detection of virus in endocrine tissues.

Authors:  A M Poma; D Bonuccelli; R Giannini; E Macerola; P Vignali; C Ugolini; L Torregrossa; A Proietti; M Pistello; A Basolo; F Santini; A Toniolo; F Basolo
Journal:  J Endocrinol Invest       Date:  2021-06-30       Impact factor: 4.256

Review 8.  COVID Obesity: A One-Year Narrative Review.

Authors:  Diana L Palacios Ovalle; Susana Rodrigo-Cano; Aránzazu González; Carla Soler; Ana I Catalá-Gregori; J Francisco Merino-Torres; Jose M Soriano
Journal:  Nutrients       Date:  2021-06-16       Impact factor: 6.706

9.  Early changes in laboratory parameters are predictors of mortality and ICU admission in patients with COVID-19: a systematic review and meta-analysis.

Authors:  Szabolcs Kiss; Noémi Gede; Péter Hegyi; Dávid Németh; Mária Földi; Fanni Dembrovszky; Bettina Nagy; Márk Félix Juhász; Klementina Ocskay; Noémi Zádori; Zsolt Molnár; Andrea Párniczky; Péter Jenő Hegyi; Zsolt Szakács; Gabriella Pár; Bálint Erőss; Hussain Alizadeh
Journal:  Med Microbiol Immunol       Date:  2020-11-21       Impact factor: 3.402

Review 10.  Obesity and COVID-19: A jigsaw puzzle with still missing pieces.

Authors:  Konstantinos Michalakis; Grigorios Panagiotou; Ioannis Ilias; Kalliopi Pazaitou-Panayiotou
Journal:  Clin Obes       Date:  2020-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.